CN101220056A - Use of fluoroquinolone containing phosphoric acid ester group - Google Patents
Use of fluoroquinolone containing phosphoric acid ester group Download PDFInfo
- Publication number
- CN101220056A CN101220056A CNA2007100036639A CN200710003663A CN101220056A CN 101220056 A CN101220056 A CN 101220056A CN A2007100036639 A CNA2007100036639 A CN A2007100036639A CN 200710003663 A CN200710003663 A CN 200710003663A CN 101220056 A CN101220056 A CN 101220056A
- Authority
- CN
- China
- Prior art keywords
- compound
- salt
- general formula
- oxygen
- quinolizine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of fluoroquinolone compounds containing phosphate groups and belongs to the pharmacochemistry field. The fluoroquinolone compounds containing phosphate groups have the structure shown as general formula I, wherein the 5-methyl is in (S)-configuration, (R)-configuration or (R/S)-configuration. The invention provides the compounds shown as the general formula (I), racemes and various optical isomers of the compounds, various forms of crystals, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and hydrolysable esters and drug composites containing the compounds shown as the general formula (I), the application of the compound in preparation of drugs for animal or human infectious diseases, particularly animal or human infectious diseases caused by bacteria such as aerobic Gram-positive bacteria and Gram-negative bacteria, anaerobic Gram-positive bacteria and Gram-negative bacteria, etc., as active materials.
Description
The application is the division of Chinese patent application 200710000558.X.
Original application day: 2007-1-12
Original applying number: 200710000558.X
Original application invention and created name: the fluoroquinolone compound of phosphoric acid ester group, Preparation Method And The Use
Technical field
The present invention relates to fluoroquinolone compound, the Preparation Method And The Use of phosphoric acid ester group, belong to the pharmaceutical chemistry field.
Background technology
(J Med Pharm Chem 1962,5:1063-1065) since the appearance, through 40 years of development, quinolones developed into the antibacterials that are only second to cynnematin, has nearly 20 kinds to be widely used in clinical from Nalidixic Acid in 1962.(Nadifloxacin OPC-7251) is the carbostyril family antibacterial drugs with tricyclic structure to nadifloxacin, and it is Japanese Otsuka company nineteen eighty-three invention [United States Patent (USP), 4399134; Japanese Patent, 5890511].Nadifloxacin at first went on the market in Japan with raceme in 1993, was used for the treatment of acne and other skin infections disease [Drug of the future 1990,15 (7), 685] as external preparation.Nadifloxacin is a raceme, can split into i.e. (S)-(-)-nadifloxacin and (R)-(+)-nadifloxacin of two isomer, and its main biological activity derives from (S)-isomer.(S)-(-)-anti-microbial activity of nadifloxacin be (R)-(+)-nadifloxacin 64-256 doubly, be 2 times of [Tetrahedron:Asymmmetry, 1995 (6), 245 of raceme nadifloxacin; JP63192753; Chem.Pharm.Bull 1996,44 (4), and 642].(S)-(-)-nadifloxacin is to Gram-negative bacteria, gram-positive microorganism, aerophil and anerobe, comprises resistant organism, has efficient, broad-spectrum antibacterial activity [AntimicribAgents Chemother.2004,48 (9), 3338; Antimicrib AgentsChemother.2004,48 (8), 3188].
Existing patent disclosure many with (S)-(-)-compound or the derivative of nadifloxacin similar structures, for example PCT patent [WO00/68229] discloses the salt of derivative, crystalline hydrate, various organic acid and the mineral acid of a series of (S)-(-)-nadifloxacin.
PCT patent [WO01/85728] discloses a series ofly has the active 9-of anti-MRSA position piperidine ring together with dibasic novel (S)-(-)-nadifloxacin derivative.
PCT patent [WO03/050107] and the patent disclosure quoted thereof 7-position or the cyclosubstituted Carbostyril derivative of 9-position piperidines (comprising 4-amino piperidine and 4-hydroxy piperidine).
PCT patent [WO01/85095] discloses the preparation method and the purposes of (S)-(-)-nadifloxacin arginic acid salt and crystalline hydrate thereof, and (S)-(-)-nadifloxacin arginic acid salt tetrahydrate (WCK771) is better because of its stability, be easy to preparation and entered I clinical study [J.Med.Chem.2005,48 (16), 5232].
No matter be nadifloxacin or (S)-(-)-nadifloxacin, its water solubility is all very little.(S)-(-)-and nadifloxacin water-soluble hardly (in 28 ℃ of water solubilities position 0.06 mg/ml only), can not drug administration by injection, oral absorption is poor, be difficult to the systemic infection treatment, thereby limited its application [J.Med.Chem.2005,48 (16), 5232] as medicine.(S)-(-)-nadifloxacin arginic acid salt tetrahydrate xln compares with (S)-(-)-nadifloxacin, though water-soluble making moderate progress, but the water-soluble of its 1.3 mg/ml can not be satisfactory, and (S)-(-)-nadifloxacin arginic acid salt tetrahydrate xln oral absorption effect is poor.
Summary of the invention
First purpose of the present invention be to provide a kind of below the new intermediate compound of fluoroquinolone compound of preparation phosphoric acid ester group of general formula (IV):
Among the general formula I V, described R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
8Alkoxyl group or C
1-C
3Alkylamino radical.
Second purpose of the present invention be to provide a kind of below the new intermediate compound of fluoroquinolone compound of preparation phosphoric acid ester group of general formula (VII):
R among the general formula VII
2, R
3Can independently be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
The 3rd purpose of the present invention is to provide a kind of preparation method of fluoroquinolone compound of phosphoric acid ester group.
The 4th purpose of the present invention is to provide the preparation method of the fluoroquinolone compound of another kind of phosphoric acid ester group.
The 5th purpose of the present invention is to provide the purposes of fluoroquinolone compound aspect preparation treatment infectious disease medicament of phosphoric acid ester group.
The fluoroquinolone compound of above-mentioned phosphoric acid ester group has the described structure of following general formula I:
Wherein:
R
1Be the benzyl shown in H, the blocking group that maybe can be hydrolyzed that can slough or the general formula (II), and can substituted benzyl;
R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
5 methyl in the above-mentioned general formula I can be (S)-configuration or (R)-configuration or (R/S)-configurations.
Carbostyril compound shown in the general formula I comprises raceme, various optical isomer, all cpds crystal formation, pharmacy acceptable salt, pharmaceutically acceptable hydrate or solvate, hydrolyzable ester.
Described pharmacy acceptable salt can be inorganic salt or organic salt.
Above-mentioned " alkyl " is the straight or branched alkane chain of saturated, unsaturated, replacement, non-replacement.Unless special the qualification, it can be following group: methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl, the tertiary butyl, amyl group, isopentyl, neo-pentyl, tert-pentyl, the 1-methyl butyl, the 2-methyl-propyl, hexyl, isohexyl, the 1-methyl amyl, the 2-methyl amyl, the 3-methyl amyl, the 2-methyl butyl, 1, the 1-dimethylbutyl, 1, the 2-dimethylbutyl, 1, the 3-dimethylbutyl, 2, the 3-dimethylbutyl, 3, the 3-dimethylbutyl, the 1-ethyl-butyl, the 2-ethyl-butyl, 1,1,2-trimethylammonium propyl group, 1,2,2-trimethylammonium propyl group, 1-ethyl-1-methyl-propyl, 1-ethyl-2-methyl-propyl etc.
In above-mentioned these groups, carbonatomss such as preferable methyl, ethyl, propyl group, sec.-propyl, butyl are 1-4 alkyl; More preferably methyl, ethyl and propyl group; Most preferably be methyl or ethyl.
Described " can substituted alkyl ", " can substituted benzyl " respectively expression can be at random by halogen atom, alkyl, alkoxyl group, acyloxy ,-OH ,-NH
2,-NO
2" alkyl " or " benzyl " that ,-NHAc group replaces.
Described " pharmacy acceptable salt " can be the salt that forms with alkali, as the salt that forms with mineral alkalis such as sodium, potassium, calcium, and ammonium salt, methylamine salt, ethylamine salt, ethanolamine salt etc., or the salt that forms with basic aminoacidss such as Methionin, arginine, ornithines.
Preferred compound of the present invention is (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7), it is the compound with optical purity, structural formula is:
Another preferred compound of the present invention is 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10), it is the racemic modification compound, structural formula is:
First purpose of the present invention be to provide a kind of below the new intermediate compound of fluoroquinolone compound of preparation phosphoric acid ester group of general formula (IV):
Among the general formula I V, described R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
In preferred formula provided by the invention (IV) compound, R
2Be H, i.e. (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6);
With 9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 9).
Second purpose of the present invention be to provide a kind of below the new intermediate compound of fluoroquinolone compound of preparation phosphoric acid ester group of general formula (VII):
R among the general formula VII
2, R
3Can independently be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
In preferred formula provided by the invention (VII) compound, R
2, R
3Be H, i.e. (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-benzyl carboxylate (compound 7a).
For realizing the 3rd purpose of the present invention, preparation method of the present invention may further comprise the steps:
A, 1-tertbutyloxycarbonyl-4-hydroxy piperidine is dissolved in the polar aprotic solvent, add alkali, under-40～50 ℃, drip two benzyloxy phosphoryl chloride or derivatives thereof compounds (shown in the general formula III), reacted 0.5～48 hour, reaction solution obtains 1-(tertbutyloxycarbonyl)-4-piperidyl dibenzyl phosphate (compound 3) through washing, drying, filtration, concentrated, column chromatography;
B, compound 3 is dissolved in the polar aprotic solvent, adding acid at-30 ℃ to the scope between the solvent refluxing temperature reacts, until raw material disappearance (taking off the tertbutyloxycarbonyl protecting group), concentrating under reduced pressure then, reclaim solvent, residue is neutralized the water organic solvent extraction with alkali, organic solvent phase drying, concentrated obtains 4-piperidyl dibenzyl phosphate (compound 4) or derivatives thereof;
C, 4-piperidyl dibenzyl phosphate (compound 4) or derivatives thereof with (S)-(O-B)-diacetoxy-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxyl) boric acid ester (compound 5) or (S)-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 5a) or their raceme, in polar aprotic solvent, reacted 1～48 hour under in room temperature to the solvent refluxing temperature, reaction solution concentrates, add water stir suspension, filter solid, solid is added in the mixed solution of being made up of polar aprotic solvent and alkali, stir to clarify, regulate pH to 2-4, with with the extraction of the immiscible polar aprotic solvent of water, extraction liquid solvent phase drying, filter, concentrate, will concentrate back product column chromatography, obtain (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6) or derivatives thereof;
D, compound 6 or derivatives thereofs are dissolved in the polar solvent, add catalyst hydrogenation, end to no longer absorbing hydrogen, filter out catalyzer, gained solid water dissolution is crossed the filtering insolubles, filtrate is extracted, water dewater (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or its raceme (compound 10).
Among the above-mentioned steps A, the general formula of described two benzyloxy phosphoryl chloride or derivatives thereofs is:
In the general formula (III), described R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
The preferred di-p-methoxy benzyloxy of described two benzyloxy phosphoryl chloride derivatives phosphoryl chloride, two pairs of nitro benzyloxy phosphoryl chlorides or two pairs of methyl benzyloxy phosphoryl chlorides.
Described polar aprotic solvent can be selected pyridine for use, acetonitrile, benzene, toluene, chloroform, methylene dichloride, tetrahydrofuran (THF), dimethyl formamide or dimethyl sulfoxide (DMSO);
Described alkali can be organic bases or mineral alkali;
Organic bases can be a pyridine, triethylamine, 1,8-diazabicyclo [5,4,0] undecane-7-alkene (DBU);
Mineral alkali can be a sodium hydroxide, potassium hydroxide, yellow soda ash, salt of wormwood etc.;
When polar aprotic solvent adopts pyridine,, can no longer add alkali because pyridine is a basic solvent;
The preferred reaction conditions of steps A is: methylene dichloride is a solvent, and pyridine is an alkali, room temperature reaction 24 hours.
Among the above-mentioned steps B,
Described polar aprotic solvent can be chloroform, methylene dichloride, acetonitrile, tetrahydrofuran (THF), dioxane, ether etc.;
Added acid is trifluoroacetic acid, hydrochloric acid, Hydrogen bromide etc.;
The preferred reaction conditions of step B is: with methylene dichloride is solvent, and trifluoroacetic acid is acid, and at room temperature reaction disappears until raw material;
Among the above-mentioned steps C,
Described polar aprotic solvent can be selected pyridine, acetonitrile, benzene, toluene, chloroform, methylene dichloride, tetrahydrofuran (THF), dimethyl formamide, dimethyl sulfoxide (DMSO) etc. for use;
Described alkali can be organic bases or mineral alkali;
Organic bases can be a pyridine, triethylamine, 1,8-diazabicyclo [5,4,0] undecane-7-alkene (DBU);
Mineral alkali can be a sodium hydroxide, potassium hydroxide, yellow soda ash, salt of wormwood etc.;
When polar aprotic solvent adopts pyridine,, can no longer add alkali because pyridine is a basic solvent;
The solvent that is used to extract is a chloroform, methylene dichloride, ether, methyl tert-butyl ether and ethyl acetate;
The preferred reaction conditions of step C is: acetonitrile is a solvent, and pyridine is an alkali, and 60 ℃ were reacted 6 hours down.
Among the described step C, (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6) has following feature: [α]
D 21 ℃=-156.8 ° of (c=0.308g/100ml, CDCl
3).MS(ESI)m/z(％)：620.2(M
+，100)。
1H-NMR (CDCl
3) δ: 1.51 (3H, d, J=6.74Hz, C
5-CH
3), 1.85-2.02 (m, 4H, piperidine ring C
3-H and C5-H), 2.14-2.20 (2H, m, female ring C
6-H), 2.83-3.28 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.51-4.56 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the benzyl), 7.26-7.38 (10H, m, phenyl ring hydrogen on the benzyl), 8.00 (1H, d, J=12.2Hz, female ring C
10-H), 8.68 (1H, s, female ring C
3-H).
Among the above-mentioned steps D,
Described catalyzer is metallic catalyzer, can be to contain palladium, nickel, aluminium, the composite metal catalyst of ruthenium or their arbitrary proportion; The palladium-carbon catalyst that preferably contains 0.1～50% palladium;
Described polar solvent is polar aprotic solvent or polar aprotic solvent;
Described polar aprotic solvent can be an ethyl acetate, methylene dichloride, tetrahydrofuran (THF) or dioxane;
Described polar aprotic solvent can be a methyl alcohol, ethanol, Virahol, acetate or water;
Temperature of reaction can be-30 ℃ to the scope of solvent refluxing temperature, the reaction times is greater than 0.5 hour, no longer absorb hydrogen to reaction system till;
Reaction pressure can all can be carried out under 50 normal atmosphere smoothly at normal pressure (1 normal atmosphere).
Step D preferred reaction conditions is: under the normal temperature and pressure, tetrahydrofuran (THF) is a solvent, and 10% palladium carbon is catalyzer, and the system that is reacted to no longer absorbs hydrogen and ends, remove by filter catalyzer, reclaim solvent, the residue water dissolution is filtered insolubles, water removes anhydrate (underpressure distillation or lyophilize), can obtain (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7).
Compound 2 can be prepared according to literature method [Bioorg.Med.Chem 11, (2003), 2519-2527], but compound 5 or compound 5a reference literature method [Chem.Pharm.Bull 1996,44 (4), 642] are prepared.
When compound 5 or 5a are raceme, obtain 9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 9) has following feature: MS (ESI) m/z (%): 620.2 (M
+, 100).
1H-NMR (CDCl
3) δ: 1.51 (3H, d, J=6.74Hz, C
5-CH
3), 1.85-2.02 (m, 4H, piperidine ring C
3-H and C5-H), 2.14-2.20 (2H, m, female ring C
6-H), 2.83-3.28 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.51-4.56 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the benzyl), 7.26-7.38 (10H, m, phenyl ring hydrogen on the benzyl), 8.00 (1H, d, J=12.2Hz, female ring C
10-H), 8.68 (1H, s, female ring C
3-H).
Compound 9 promptly obtains 9-fluoro-8-[4-(phosphate-based)-1-piperidines through catalytic hydrogenation]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
Said process representative example of the present invention is illustrated as follows:
X is a fluorine atom, bromine atoms.
Among the above-mentioned preparation method of the present invention, among its step C, compound 5 or 5a also can use (S)-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-benzyl carboxylate (compound 5b) substitutes and to react, and obtains (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-benzyl carboxylate (compound 7a, R
3=H) have a following feature, MS (ESI) m/z (%): 710.2 (M
+, 100).
1H-NMR (CDCl
3) δ: 1.50 (3H, d, J=6.74Hz, C
5-CH
3), 1.86-2.04 (m, 4H, piperidine ring C
3-H and C5-H), 2.10-2.22 (2H, m, female ring C
6-H), 2.80-3.30 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.50-4.58 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the phosphoric acid ester benzyl), 5.30 (2H, m, methylene radical hydrogen on the carboxylicesters benzyl), 7.19-7.40 (15H, m, phenyl ring hydrogen on the benzyl), 8.10 (1H, d, J=12.2Hz, female ring C
10-H), 8.60 (1H, s, female ring C
3-H).
Compound 7a obtains (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines through shortening]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7).
Above-mentioned steps is specially: 4-piperidyl dibenzyl phosphate or derivatives thereof with (S)-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-benzyl carboxylate (compound 5b) in polar aprotic solvent, reacted 1～48 hour under in room temperature to the solvent refluxing temperature, reaction solution concentrates, add water stir suspension, filter the crude product of compound 7a.Compound 7a crude product need not be further purified and promptly can be used for next step reaction.With compound 7a dissolving crude product in polar solvent, add catalyst hydrogenation, end to no longer absorbing hydrogen, filter out catalyzer, gained solid water dissolution, cross the filtering insolubles, with filtrate extraction, water dewater solid, i.e. (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7).
Said process representative example of the present invention is illustrated as follows:
R
3Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.X is a fluorine atom, bromine atoms or chlorine atom.
Among the above-mentioned steps A, but compound 5b reference [Chem.Pharm.Bull 1996,44 (4), 642], and esterification process makes 5a and the reaction of various benzylalcohol routinely.
In the aforesaid method, replace 5b, can obtain 9-fluoro-8-[4-(phosphate-based)-1-piperidines with racemization 5b]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
In order to realize the 4th purpose of the present invention, its technical scheme can be as follows:
Preparation method of the present invention (one) is made of following steps:
A, (S)-(-)-nadifloxacin (compound 1) [(S)-(-)-and 9-fluoro-8-(4-hydroxyl-1-piperidines)-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid, Chem.Pharm.Bull 1996,44 (4), 642] or nadifloxacin [United States Patent (USP), 4399134; Japanese Patent, 5890511] and two benzyloxy phosphoryl chloride or derivatives thereofs (shown in the general formula III), in polar aprotic solvent, alkali exists down, arrives in the scope of solvent refluxing temperature at-20 ℃, reacts 1～48 hour, obtains general formula I V compound;
The general formula of described two benzyloxy phosphoryl chloride or derivatives thereofs is:
Among general formula III and the general formula I V, described R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
B, general formula I V compound are in polar solvent; under the condition that catalyzer exists; take off blocking group; obtain (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H; 5H-benzo [i; j] quinolizine-2-carboxylic acid (compound 7) or 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
In the described steps A,
Described polar aprotic solvent can be a pyridine, acetonitrile, benzene, toluene, chloroform, methylene dichloride, tetrahydrofuran (THF), dimethyl formamide or dimethyl sulfoxide (DMSO);
Described alkali can be organic bases or mineral alkali; Wherein, organic bases can be a pyridine, triethylamine, 1,8-diazabicyclo [5,4,0] undecane-7-alkene (DBU); Mineral alkali can be sodium hydroxide, potassium hydroxide, yellow soda ash or salt of wormwood.
Above-mentioned polar aprotic solvent owing to himself be basic solvent, can not add alkali if during pyridine.
The preferred di-p-methoxy benzyloxy of described two benzyloxy phosphoryl chloride derivatives phosphoryl chloride, two pairs of nitro benzyloxy phosphoryl chlorides or two pairs of methyl benzyloxy phosphoryl chlorides.(be R
2Methoxyl group, nitro, methyl for contraposition)
The most preferably reaction conditions of this step is: to normal temperature, is solvent with the methylene dichloride in the ice bath temperature, is alkali with the pyridine, reacts 24 hours.
Among the described step B,
Described catalyzer is metallic catalyzer, can be the composite metal catalyst that contains palladium, nickel, aluminium, ruthenium or their arbitrary proportion;
Preferred catalyzer is the palladium-carbon catalyst that contains the 0.1-50% palladium;
Described polar solvent can be polar aprotic solvent or polar aprotic solvent;
Described polar aprotic solvent can be ethyl acetate, methylene dichloride, tetrahydrofuran (THF), dioxane;
Described polar aprotic solvent can be methyl alcohol, ethanol, Virahol, acetate, water or be fit to other solvent of the present invention;
Described temperature of reaction is for being higher than-30 ℃, to the scope of polarity solvent refluxing temperature;
Reaction times is greater than 0.5 hour, till reaction system no longer absorbs hydrogen;
Reaction pressure is that (1 normal atmosphere) all can carry out in this scope under 50 normal atmosphere smoothly under the normal pressure.
Preferred reaction conditions is: under the normal temperature and pressure, be solvent with the tetrahydrofuran (THF), react under 10% palladium-carbon catalyst, no longer absorb hydrogen up to system; Remove by filter catalyzer then, reclaim solvent, the residue water dissolution, filter insolubles, water promptly gets (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines after removing and anhydrating]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or compound 10; Dewater and to adopt underpressure distillation or cryodesiccated mode.
The method of the invention (one) representative example is illustrated as follows:
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines as required]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) can make pharmaceutically acceptable inorganic or organic salt, hydrate or solvate, various crystal formations and pharmaceutical composition.
Preparation method of the present invention (two) may further comprise the steps:
A, (S)-(-)-nadifloxacin (compound 1) [(S)-(-)-and 9-fluoro-8-(4-hydroxyl-1-piperidines)-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid, Chem.Pharm.Bull 1996,44 (4), 642] or nadifloxacin [United States Patent (USP), 4399134; Japanese Patent, 5890511], with dibenzyl diisopropylaminoethyl phosphorous acid ester or derivatives thereof in polar aprotic solvent, reaction adds oxygenant then in the presence of alkali, obtains general formula I V compound by oxidation;
The general formula of described dibenzyl diisopropylaminoethyl phosphorous acid ester or derivatives thereof is:
R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
R
3And R
4Be identical or different C
1-C
6Alkyl.
B, general formula I V compound are in polar solvent; under the condition that catalyzer exists; take off blocking group; obtain (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H; 5H-benzo [i; j] quinolizine-2-carboxylic acid (compound 7) or 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10)
Among the above-mentioned steps A:
Described polar aprotic solvent can be selected pyridine, acetonitrile, benzene, toluene, chloroform, methylene dichloride, tetrahydrofuran (THF), dimethyl formamide or dimethyl sulfoxide (DMSO) for use.
Described alkali can be organic bases or mineral alkali;
Organic bases can be the 1H-tetrazolium, pyridine, triethylamine, 1,8-diazabicyclo [5,4,0] undecane-7-alkene (DBU);
Mineral alkali can be a sodium hydroxide, potassium hydroxide, yellow soda ash, salt of wormwood;
When adopting basic solvent such as pyridine, can not add alkali.
The preferred di-p-methoxy benzyl of dibenzyl diisopropylaminoethyl phosphite derivative thing diisopropylaminoethyl phosphorous acid ester, two pairs of nitrobenzyl diisopropylaminoethyl phosphorous acid esters or two pairs of methyl-benzyl diisopropylaminoethyl phosphorous acid esters, promptly among the general formula V, R
2Methoxyl group, nitro, methyl for contraposition.
Described oxygenant can be selected metachloroperbenzoic acid, benzoyl hydroperoxide, hydrogen peroxide for use, and is fit to other oxygenant of the present invention or composite oxidant.
Optimum reaction condition is: ice bath is under normal temperature, and methylene dichloride is a solvent, and the 1H-tetrazolium is alkali reaction 5-7 hour.
Among the described step B,
Described catalyzer is metallic catalyzer, can be the composite metal catalyst that contains palladium, nickel, aluminium, ruthenium or their arbitrary proportion;
Preferred catalyzer is the palladium-carbon catalyst that contains the 0.1-50% palladium;
Described polar solvent can be polar aprotic solvent or polar aprotic solvent;
Described polar aprotic solvent can be chloroform, acetonitrile, ethyl acetate, methylene dichloride, tetrahydrofuran (THF), dioxane;
Described polar aprotic solvent can be methyl alcohol, ethanol, Virahol, acetate, water or be fit to other solvent of the present invention;
Described temperature of reaction is for being higher than-30 ℃, to the scope of polarity solvent refluxing temperature;
Reaction times is greater than 0.5 hour, till reaction system no longer absorbs hydrogen;
Reaction pressure is that (1 normal atmosphere) all can carry out in this scope under 50 normal atmosphere smoothly under the normal pressure.
Preferred reaction conditions is: under the normal temperature and pressure, be solvent with the tetrahydrofuran (THF), react under 10% palladium-carbon catalyst, no longer absorb hydrogen up to system; Remove by filter catalyzer then, reclaim solvent, the residue water dissolution, filter insolubles, water promptly gets (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines after removing and anhydrating]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or compound 10; Dewater and to adopt underpressure distillation or cryodesiccated mode.
The method of the invention (two) representative example is illustrated as follows:
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines as required]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or compound 10 can make pharmaceutically acceptable inorganic or organic salt, hydrate or solvate, various crystal formations and pharmaceutical composition.
Preparation method of the present invention (three) may further comprise the steps:
A, (S)-(-)-nadifloxacin benzyl ester or nadifloxacin benzyl ester or derivatives thereof (shown in the general formula VI),
With two benzyloxy phosphoryl chloride or derivatives thereofs (shown in the general formula III), in polar aprotic solvent, alkali exists down, arrives in the scope of solvent refluxing temperature at-20 ℃, reacts 1～48 hour, obtains general formula VII compound; Or with dibenzyl diisopropylaminoethyl phosphorous acid ester or derivatives thereof (shown in the general formula V), in polar aprotic solvent, in the presence of alkali the reaction, add oxygenant then, obtain general formula VII compound by oxidation;
General formula VII is as follows:
R among general formula VI and the general formula VII
2, R
3Can independently be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical.
B, general formula VII compound are in polar solvent; under the condition that catalyzer exists; take off blocking group; obtain (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H; 5H-benzo [i; j] quinolizine-2-carboxylic acid (compound 7) or 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
Described nadifloxacin benzyl ester or derivatives thereof (shown in the general formula VI) but reference literature [Chem.Pharm.Bull1996,44 (4), 642; Chem.Pharm.Bull 1989,37 (8), and 2103] method, prepare by universal method in the prior art.
Described nadifloxacin benzyl ester or derivatives thereof can be (S)-(-)-nadifloxacin benzyl ester or derivatives thereof or raceme nadifloxacin benzyl ester or derivatives thereof, preferred (S)-(-)-nadifloxacin benzyl ester or derivatives thereof.
In the described steps A,
Described polar aprotic solvent can be pyridine, acetonitrile, benzene, toluene, chloroform, methylene dichloride, tetrahydrofuran (THF), dimethyl formamide or dimethyl sulfoxide (DMSO).
Described alkali can be organic bases or mineral alkali; Wherein, organic bases can be a pyridine, triethylamine, 1,8-diazabicyclo [5,4,0] undecane-7-alkene (DBU); Mineral alkali can be sodium hydroxide, potassium hydroxide, yellow soda ash or salt of wormwood.
Above-mentioned polar aprotic solvent owing to himself be basic solvent, can not add alkali if during pyridine.
The preferred di-p-methoxy benzyloxy of described two benzyloxy phosphoryl chloride derivatives phosphoryl chloride, two pairs of nitro benzyloxy phosphoryl chlorides or two pairs of methyl benzyloxy phosphoryl chlorides.
The preferred di-p-methoxy benzyl of dibenzyl diisopropylaminoethyl phosphite derivative thing diisopropylaminoethyl phosphorous acid ester, two pairs of nitrobenzyl diisopropylaminoethyl phosphorous acid esters or two pairs of methyl-benzyl diisopropylaminoethyl phosphorous acid esters.
Described oxygenant can be selected metachloroperbenzoic acid, benzoyl hydroperoxide, hydrogen peroxide for use, and is fit to other oxygenant of the present invention or composite oxidant.
Among the described step B,
Described catalyzer is metallic catalyzer, as contains the composite metal catalyst of palladium, nickel, aluminium, ruthenium or their arbitrary proportion;
Preferred catalyzer is the palladium-carbon catalyst that contains the 0.1-50% palladium.
Described polar solvent can be polar aprotic solvent or polar aprotic solvent.
Described polar aprotic solvent can be ethyl acetate, methylene dichloride, tetrahydrofuran (THF), dioxane;
Described polar aprotic solvent can be methyl alcohol, ethanol, Virahol, acetate, water or be fit to other solvent of the present invention.
Described temperature of reaction is for being higher than-30 ℃, to the scope of polarity solvent refluxing temperature;
Reaction times is greater than 0.5 hour, till reaction system no longer absorbs hydrogen;
Reaction pressure is that (1 normal atmosphere) all can carry out in this scope under 50 normal atmosphere smoothly under the normal pressure.
Preferred reaction conditions is: under the normal temperature and pressure, be solvent with the tetrahydrofuran (THF), react under 10% palladium-carbon catalyst, no longer absorb hydrogen up to system; Remove by filter catalyzer then, reclaim solvent, the residue water dissolution, filter insolubles, water promptly gets (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines after removing and anhydrating]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).Dewater and to adopt underpressure distillation or cryodesiccated mode.
The method of the invention (three) representative example is illustrated as follows:
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10), according to actual needs, can make pharmaceutically acceptable inorganic salt or organic salt, hydrate or solvate, and various crystal formation and pharmaceutical composition.
Particular compound numbering wherein, structural formula, title see the following form 1.
The structural formula of table 1 representative compounds and title
The present invention also provides compound shown in the general formula (I) and raceme and various optical isomer, various crystal formations, pharmaceutically acceptable inorganic or organic salt, described pharmacy acceptable salt can be a sodium salt, sylvite, calcium salt, ammonium salt, methylamine salt, ethylamine salt, ethanolamine salt, lysine salt, arginic acid salt or ornithine salt, hydrate or solvate, hydrolyzable ester, the pharmaceutical composition that contains compound shown in the general formula (I) is treated particularly aerobic gram-positive microorganism of animal and human's infectious diseases and Gram-negative bacteria as active substance in preparation, purposes on the bacterial animal or humans' of bacterium such as anaerobism gram-positive microorganism and Gram-negative bacteria the infectious disease medicament.
Above-mentioned animal or human catches preferably by streptococcus aureus methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, osculant staphylococcus, Staphylococcus saprophyticus, A group streptococcus (micrococcus scarlatinae), B group streptococcus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, streptococcus agalactiae, Streptococcus viridans, hemophilus influenzae, haemophilus parainfluenzae, escherichia coli, Klebsiella Pneumoniae, citrobacter, enteroaerogen, enterobacter cloacae, acinetobacter, Pseudomonas aeruginosa, enterobacter agglomerans, serratia marcesens, Salmonella typhi, Bacillus proteus, dysentery bacterium is had a liking for the Fructus Hordei Germinatus Flavobacterium, bacteroides fragilis, moraxelle catarrhalis causes.
More preferably by streptococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, hemophilus influenzae, escherichia coli, dysentery bacterium, Pseudomonas aeruginosa, serratia marcesens, Salmonella typhi, moraxelle catarrhalis cause catching of above-mentioned animal or human.
Embodiment
The present invention is further elaborated below in conjunction with embodiment, but these embodiment never are any limitation of the invention.Among all embodiment, fusing point is measured with MEL-TEMP fusing point instrument, and thermometer is not proofreaied and correct;
1H-NMR VarianMercury 400 nuclear magnetic resonance analyser records, chemical shift is represented with δ (ppm); Separate with the unaccounted 200-300 order that is of silica gel, the developping agent solvent ratio is a volume ratio.
Embodiment 1-1
The preparation of 1-(tertbutyloxycarbonyl)-4-piperidyl dibenzyl phosphate (compound 3).
[Bioorg.Med.Chem 11 for 1-tertbutyloxycarbonyl-4-hydroxy piperidine, (2003), 2519-2527] (8.04g0.04mol) be dissolved in the methylene dichloride (60ml) that contains pyridine (4ml), the ice bath cooling drips down and contains two benzyloxy phosphoryl chlorides (17.8g, 0.06mol) dichloromethane solution (20ml), dropwise the back stirred overnight at room temperature.The reaction solution of gained is used 1N hydrochloric acid soln, saturated NaHCO respectively
3Washing, the dichloromethane solution anhydrous sodium sulfate drying filters, and concentrating under reduced pressure gained residuum carries out column chromatography (methylene chloride=50: 1) and gets the flaxen oily matter compound 3 of 11.0g, yield 63.0%.
1H-NMR (CDCl
3) δ: 1.42 (s, 9H, Boc), 1.60-1.64 (m, 2H, piperidine ring C
3-H and C
5-H), 1.74-1.81 (m, 2H, piperidine ring C
3-H and C
5-H), 3.13-3.21 (m, 2H, piperidine ring C
2-H and C
6-H), 3.52-3.59 (m, 2H, piperidine ring C
2-H and C
6-H), 4.48-4.50 (m, 1H, piperidine ring C
4-H), 4.97-5.06 (m, 4H, methylene radical hydrogen), 7.26-7.38 (m, 10H, phenyl ring hydrogen).
Embodiment 1-2
The preparation of 4-piperidyl dibenzyl phosphate (compound 4).
1-(tertbutyloxycarbonyl)-4-piperidyl dibenzyl phosphate (compound 3) compound 3 (8.74g 0.02mol) is dissolved in the methylene dichloride (30ml), under the ice bath cooling, add with trifluoroacetic acid (45mL), add the back stirring at room, TLC (methylene chloride=9: 1) follows the tracks of detection reaction, concentrating under reduced pressure after reaction finishes, add ammoniacal liquor (25mL) in the gained residue, with methylene dichloride (50mL) extraction.The dichloromethane solution anhydrous sodium sulfate drying, overanxious, concentrate (6.9g) flaxen oily matter compound compound 4, yield 99.7%.
1H-NMR (CDCl
3) δ: 1.71-1.75 (m, 2H, piperidine ring C
3-H and C
5-H), 1.90-1.93 (m, 2H, piperidine ring C
3-H and C
5-H), 2.79-2.83 (m, 2H, piperidine ring C
2-H and C
6-H), 2.98-3.02 (m, 2H, piperidine ring C
2-H and C
6-H), 4.48-4.50 (m, 1H, piperidine ring C
4-H), 4.98-5.08 (m, 4H, methylene radical hydrogen), 7.26-7.37 (m, 10H, phenyl ring hydrogen).
Embodiment 1-3
(S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6).
4-piperidyl dibenzyl phosphate compound 4 (3.19g, 8.85mmol) and (S)-(O-B)-diacetoxy-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxyl) boric acid ester compound 5[Chem.Pharm.Bull 1996,44 (4), 642] (0.99g 2.43mmol) joins in the acetonitrile (20ml), reaction is 6 hours about 60 ℃, reaction solution concentrates, and the gained residuum adds entry (15ml) to be handled, and stirring at room gets suspension, filter, the solid of gained join NaOH solution (9ml, 3.5%, w/v) and in the mixed solvent formed of acetonitrile (4ml), the gained mixture becomes clarification in stirring at room up to mixture, be adjusted to PH=2～4 with concentrated hydrochloric acid, dichloromethane extraction, dichloromethane solution anhydrous sodium sulfate drying, filter, concentrating under reduced pressure gained residuum carries out column chromatography (methylene chloride=9: 1) and gets the flaxen oily matter compound 6 of 0.5g.
[α]
D 21℃-156.8°(c＝0.308g/100ml，CDCl
3)。
1H-NMR (CDCl
3) δ: 1.51 (3H, d, J=6.74Hz, C
5-CH
3), 1.85-2.02 (m, 4H, piperidine ring C
3-H and C5-H), 2.14-2.20 (2H, m, female ring C
6-H), 2.83-3.28 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.51-4.56 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the benzyl), 7.26-7.38 (10H, m, phenyl ring hydrogen on the benzyl), 8.00 (1H, d, J=12.2Hz, female ring C
10-H), 8.68 (1H, s, female ring C
3-H).
Embodiment 1-4
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7).
With (S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6) (0.7g, 1.13mmol) be dissolved in the tetrahydrofuran (THF) (30ml), adding 10% Pd/C (93mg), catalytic hydrogenation is to no longer absorbing till the hydrogen under the normal temperature and pressure, filter out catalyzer, the solid of gained stirred with distilled water wash dissolving, filter out insolubles, use the dichloromethane extraction aqueous solution again 1 time.Pressure reducing and steaming water or lyophilize obtain faint yellow solid (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid cpd 7 (357mg), yield 71.9%.
mp：178-181℃，[α]
D 20℃-316°(c＝0.300g/100ml，H
2O)。
1H-NMR (DMSO) δ: 1.41 (3H, d, J=6.74Hz), 1.74-2.15 (6H, m, piperidine ring C
3-H and C
5-H, female ring C
6-H), 2.87-3.38 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.35-4.40 (1H, m, piperidine ring C
4-H), 4.84-4.86 (1H, m, female ring C
5-H), 7.82 (1H, d, J=12.61Hz, female ring C
10-H), 8.92 (1H, s, female ring C
3-H).
HPLC detects purity: 99.15%[post: Gemini; Moving phase: methyl alcohol-2 ‰ phosphoric acid (70: 30)].
Embodiment 1-5
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7).
4-piperidyl dibenzyl phosphate compound 4 (3.19g, 8.85mmol) with (S)-(8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-2-benzyl carboxylate (compound 5b, X=F) (3.32g, 9.00mmol) join in the acetonitrile (20ml), reaction is 6 hours about 60 ℃, and reaction solution concentrates, the gained residuum adds entry (15ml) to be handled, stirring at room gets suspension, filters, and the solid of gained is the crude product of compound 7a.Get 100 milligrams of crude products carry out column chromatography (methylene chloride=9: 1) 7a.
MS(ESI)m/z(％)：710.2(M
+，100)。
1H-NMR (CDCl
3) δ: 1.50 (3H, d, J=6.74Hz, C
5-CH
3), 1.86-2.04 (m, 4H, piperidine ring C
3-H and C5-H), 2.10-2.22 (2H, m, female ring C
6-H), 2.80-3.30 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.50-4.58 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the phosphoric acid ester benzyl), 5.30 (2H, m, methylene radical hydrogen on the carboxylicesters benzyl), 7.19-7.40 (15H, m, phenyl ring hydrogen on the benzyl), 8.10 (1H, d, J=12.2Hz, female ring C
10-H), 8.60 (1H, s, female ring C
3-H).
This crude product with the identical method hydrogenation of embodiment 1-4, is obtained 0.1g compound 7.
Nuclear-magnetism, optically-active and fusing point data are identical with embodiment 1-4.
Embodiment 1-6
9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 9).
4-piperidyl dibenzyl phosphate compound 4 (3.19g, 8.85mmol) and (8,9-two fluoro-5-methyl-6,7-dihydro-1-oxygen-1H, 5H-benzo [i, j] quinolizine-[Chem.Pharm.Bull 1996,44 (4) for the 2-carboxylic acid, 642] (2.43mmol) reaction gets 0.35g compound 9 with the method identical with embodiment 1-3.
mp：69-72℃。
1H-NMR (CDCl
3) δ: 1.51 (3H, d, J=6.74Hz, C
5-CH
3), 1.85-2.02 (m, 4H, piperidine ring C
3-H and C5-H), 2.14-2.20 (2H, m, female ring C
6-H), 2.83-3.28 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.51-4.56 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the benzyl), 7.26-7.38 (10H, m, phenyl ring hydrogen on the benzyl), 8.00 (1H, d, J=12.2Hz, female ring C
10-H), 8.68 (1H, s, female ring C
3-H).
Embodiment 1-7
9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 9) (0.1g, 0.16mmol) be dissolved in the tetrahydrofuran (THF) (10ml), adding 10% Pd/C (15mg), catalytic hydrogenation is to no longer absorbing till the hydrogen under the normal temperature and pressure, filter out catalyzer, the solid of gained stirred with distilled water wash dissolving, filter out insolubles, use the dichloromethane extraction aqueous solution again 1 time.Pressure reducing and steaming water or lyophilize obtain faint yellow solid 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid cpd 10 (34.7mg), yield 48.8%.
Mp:204-207 ℃,
1H-NMR (DMSO) δ: 1.39 (3H, d, J=6.7Hz) 1.83-2.14 (6H, m, piperidine ring C
3-H and C
5-H, female ring C
6-H), 2.90-3.22 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.30-4.40 (1H, m, piperidine ring C
4-H), 4.84-4.86 (1H, m, female ring C
5-H), 7.79 (1H, d, J=12.6Hz, female ring C
10-H), 8.61 (1H, s, female ring C
3-H).
Embodiment 2-1
(S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6)
(S)-(-)-nadifloxacin (2.0mmol, 0.72g), the mixed solution that forms of pyridine (5ml) and methylene dichloride (30ml), the ice bath cooling drips two benzyloxy phosphoryl chlorides (12.g down, 4.0mmol,) methylene dichloride (10ml) solution, after dropwising, stirred overnight at room temperature, the mixed liquid of reaction is used 1 mole hydrochloric acid, saturated sodium bicarbonate aqueous solution, saturated common salt water washing, anhydrous sodium sulfate drying respectively.Filter, concentrating under reduced pressure gained residuum carries out column chromatography (methylene chloride=9: 1) and gets the flaxen oily matter 6 of 0.13g.Yield 10.4%.
Nuclear-magnetism, optically-active are identical with embodiment 1-3.
Embodiment 2-2
(S)-(-)-9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 6)
(S)-(-)-nadifloxacin (10mmol, 3.6g) and 1H-tetrazolium (0.3mol, 2.1mg) be dissolved in the methylene dichloride (50ml), [Tetrahedron 47,26, (1991) to drip dibenzyl diisopropylaminoethyl phosphorous acid ester, 4709] (4.0mmol, 1.38g), when dropwising, reaction mixture becomes clarification.Room temperature continues to stir 3 hours, and reaction is cooled to 0 ℃ of metachloroperbenzoic acid that drips down, and (30ml 0.5mol/l), adds, and continues stirring reaction 2 hours under the room temperature; Add methylene dichloride (100ml), gained solution saturated sodium bicarbonate aqueous solution, saturated common salt water washing, anhydrous sodium sulfate drying, filter, concentrating under reduced pressure, the gained residuum is carried out column chromatography (methylene chloride=50: 1), get the flaxen oily matter of 4.17g (compound 6), yield 67.3%.
Nuclear-magnetism is identical with embodiment 1-3 with the optically-active data.
Embodiment 2-3
9-fluoro-8-[4-(two benzyloxy phosphinylidyne oxygen bases)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 9)
Nadifloxacin [Japanese Patent, 5890511] (2.0mmol, 720mg) (6.0mmol 420mg) is dissolved in the methylene dichloride (10ml), drips dibenzyl diisopropylaminoethyl phosphorous acid ester [Tetrahedron47 with the 1H-tetrazolium, 26, (1991), 4709] (4.0mmol, 1.38g), when dropwising, reaction mixture becomes clarification.Room temperature continues to stir 3 hours, and reaction is cooled to 0 ℃ of metachloroperbenzoic acid that drips down, and (0.6ml 0.5mol/l), adds, and continues stirring reaction 2 hours under the room temperature.Add methylene dichloride (20ml), gained solution saturated sodium bicarbonate aqueous solution, saturated common salt water washing, anhydrous sodium sulfate drying filters, concentrating under reduced pressure gained residuum carries out column chromatography (methylene chloride=9: 1) and gets 0.8g compound 9, yield 64.5%.
Nuclear-magnetism, the fusing point data are identical with embodiment 1-6.
Embodiment 2-4
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, the preparation of 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7)
(S)-(-)-and nadifloxacin benzyl ester (compound 6a) [reference literature Chem.Pharm.Bull 1996,44 (4), and 642; Chem.Pharm.Bull 1989,37 (8), 2103. esterification preparations according to a conventional method] (20mmol, 9.0g) and 1H-tetrazolium (0.3mol, 2.1mg) be dissolved in the methylene dichloride (50ml), drip dibenzyl diisopropylaminoethyl phosphorous acid ester [Tetrahedron, 47,26, (1991), 4709] (8.0mmol, 2.76g), when dropwising, reaction mixture becomes clarification.Room temperature continues to stir 3 hours, and reaction is cooled to 0 ℃ of metachloroperbenzoic acid that drips down, and (60ml 0.5mol/l), adds, and continues stirring reaction 2 hours under the room temperature; Add methylene dichloride (220ml), gained solution saturated sodium bicarbonate aqueous solution, saturated common salt water washing, anhydrous sodium sulfate drying filters, and concentrating under reduced pressure, residue are compound 7a crude product (need not be further purified, be directly used in next step reaction).Get 100 milligrams of crude products carry out column chromatography (methylene chloride=9: 1) 7a.
MS(ESI)m/z(％)：710.2(M
+，100)。
1H-NMR (CDCl
3) δ: 1.50 (3H, d, J=6.74Hz, C
5-CH
3), 1.86-2.04 (m, 4H, piperidine ring C
3-H and C5-H), 2.10-2.22 (2H, m, female ring C
6-H), 2.80-3.30 (6H, m, piperidine ring C
2-H and C
6-H, female ring C
7-H), 4.50-4.58 (2H, m, piperidine ring C
4-H and female ring C
5-H), 5.02-5.14 (4H, m, methylene radical hydrogen on the phosphoric acid ester benzyl), 5.30 (2H, m, methylene radical hydrogen on the carboxylicesters benzyl), 7.19-7.40 (15H, m, phenyl ring hydrogen on the benzyl), 8.10 (1H, d, J=12.2Hz, female ring C
10-H), 8.60 (1H, s, female ring C
3-H).
With above-claimed cpd 7a dissolving crude product in tetrahydrofuran (THF) (150ml), the Pd/C (930mg) of adding 10%, catalytic hydrogenation is to no longer absorbing till the hydrogen under the normal temperature and pressure, filter out catalyzer, the solid of gained stirred with distilled water wash dissolving, filter out insolubles, use the dichloromethane extraction aqueous solution again 1 time.Pressure reducing and steaming water or lyophilize obtain (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, solid (2.2g) compound 7 of 5H-benzo [i, j] quinolizine-2-carboxylic acid pistac.Two step yields add up to 25.0%.
Nuclear-magnetism, optically-active, fusing point, HPLC purity are identical with embodiment 1-4.
Embodiment 3-1
Compound (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, solubleness in 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) water
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) (embodiment 1-4 is seen in preparation) solubleness in the water in the time of 25 ℃ sees the following form 2.
The water solubility of table 2 compound 7 and (S)-(-)-nadifloxacin and WCK771
As above shown in the table, The compounds of this invention (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) is than (S)-(-)-nadifloxacin and WCK771 is water-soluble improves a lot, help making various preparations, be used for the systemic infection treatment.
Embodiment 3-2
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, the j] quinolizine-intravital drug metabolism of 2-carboxylic acid (compound 7) rat
Adopting filling stomach and intravenous injection to give for two kinds and wanting approach, dosage is 20mg/kg.Every group with 4 of healthy SD rats, male female half and half, body weight 220-280g.
Rat vein gives (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] behind the quinolizine-2-carboxylic acid (compound 7) (embodiment 1-4 is seen in preparation), the ester hydrolysis takes place rapidly and generates (S)-(-)-nadifloxacin in it in blood plasma, behind the intravenously administrable 10min, nadifloxacin plasma concentration＞4 μ g/ml.Area under the drug-time curve AUC
0-tBe 4.88 ± 0.95 μ gh/ml; Average retention time MRT is 0.3 ± 0.1h; Clearance rate CL is 86.6 ± 10.5mlmin
-1Metabolite (S)-(-)-nadifloxacin is answered area under the drug-time curve AUC
0-tBe 8.50 ± 0.17 μ gh/ml; Average retention time MRT is 3.9 ± 0.7h; Clearance rate CL is 33.7 ± 4.4mlmin
-1
Rat oral gavage gives (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] behind the quinolizine-2-carboxylic acid (compound 7), be metabolized to (S)-(-)-nadifloxacin in vivo equally, (S)-(-)-nadifloxacin blood plasma reaches peak concentration C
MaxBe 3.0 ± 1.7 μ g/ml; Peak time T
MaxBe 0.5h; Area under the drug-time curve AUC
0-tBe 6.12 ± 1.46 μ gh/ml; Average retention time MRT is 6.76 ± 1.34h.
Rat vein or filling stomach give (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, behind 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7), all rapid metabolism of original shape medicine generates (S)-(-)-nadifloxacin.Intravenously administrable metabolite nadifloxacin AUC
0-tBe 8.50 ± 0.17 μ gh/ml, gastric infusion nadifloxacin AUC
0-tBe 6.12 ± 1.46 μ gh/ml, with metabolite nadifloxacin AUC
0-tCalculate, (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) is 72% at the intravital absolute bioavailability of rat.
Shown in embodiment 3-2, (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) has good oral administration biaavailability, can be oral or intravenously administrable be used for bacterial animal or human's whole body systemic infection treatment of diseases.
Embodiment 3-3
(S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) and the research of control compound Levofloxacin mouse antibacterial activity in vivo
A, experimental strain: the bacterium that is used for infection animal is clinical isolating curing the disease property bacterial strain, and staphylococcus aureus ATCC25923 is system control bacterial strain.
B, the test preparation of bacterium liquid: the 2-3 of picking test organisms single colony inoculation cultivated 18 hours for 37 ℃ in M-H meat soup, with the suitable diluted for use of 5% sterilization dry yeast liquid.
C, laboratory animal: select healthy Kunming mouse SPF level for use, body weight 18-22 gram, male and female half and half.
The mensuration of D, the minimum bacterium amount (MLD) that causes death: get healthy SPF level Kunming mouse, body weight 18-22 gram, random packet, every group of 5 mouse, the male and female dual-purpose, draw the dilution bacterium liquid of above-mentioned difference respectively abdominal injection go in the mouse body, every mouse 0.5ml, infect the continuous observation in back 7 days, and record dead mouse number, measure as minimum deadly bacterium with the minimum bacterium amount that causes mouse 100% death.With the infection dosage of this bacterium amount as the endogenous protective test.
The preparation of E, experiment medicine: 0.5%CMC (Xylo-Mucine) preparation (being used for oral administration) and 0.9% physiological saline preparation (being used for intravenously administrable) are used in the test medication respectively, and each is subjected to the reagent thing all to establish 4 dosage groups, and the group spacing is 1: 0.5.
F, infection and treatment experimental technique: laboratory animal is evenly divided into groups at random by sex, body weight, every group of 10 mouse, male and female half and half, give mouse peritoneal infectable infection bacterium liquid respectively, 0.5ml/ mouse, infected back 1 hour, that gives mouse oral administration gavage or intravenous injection different concns respectively is subjected to reagent liquid, every mouse 0.5ml/20g.The mouse of oral administration gavage is irritated stomach once in first administration after 4 hours again, observes the death condition of record mouse after the administration.Establish the infection control group simultaneously, record infects dead mouse number in back seven days.
G, experimental result see Table 3.
Table 3 (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, antibacterial experiment result in 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) body.
P.o: oral
Iv: intravenous drip
Table 3 (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, antibacterial experiment result in 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) body
The present invention as shown in Table 3 (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) all has the excellent antibiotic effect and obviously is better than existing medicine Levofloxacin bacterium bacterium such as aerobic gram-positive microorganism and Gram-negative bacteria, anaerobism gram-positive microorganism and Gram-negative bacteria and resistant organism.
With embodiment 3-3, the present invention is to the carbostyril compound and the raceme thereof of described general formula I, various photoisomers, various crystal formations, pharmaceutically acceptable inorganic or organic salt, described pharmacy acceptable salt can be a sodium salt, sylvite, calcium salt, ammonium salt, methylamine salt, ethylamine salt, ethanolamine salt, lysine salt, arginic acid salt or ornithine salt, pharmaceutically acceptable hydrate or solvate, hydrolyzable ester, the pharmaceutical composition that contains compound shown in the general formula (I), carry out the research of mouse antibacterial activity in vivo with the control compound Levofloxacin respectively, experimental result shows, similar to embodiment 3-3 conclusion, can be used for preparation treatment particularly aerobic gram-positive microorganism of animal and human's infectious diseases and Gram-negative bacteria as active substance, purposes on the bacterial animal or humans' of bacterium such as anaerobism gram-positive microorganism and Gram-negative bacteria the infectious disease medicament, and the carbostyril compound of described general formula I is preferably (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7) or be 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
Above-mentioned animal or human catches preferably by streptococcus aureus methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, osculant staphylococcus, Staphylococcus saprophyticus, A group streptococcus (micrococcus scarlatinae), B group streptococcus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, streptococcus agalactiae, Streptococcus viridans, hemophilus influenzae, haemophilus parainfluenzae, escherichia coli, Klebsiella Pneumoniae, citrobacter, enteroaerogen, enterobacter cloacae, acinetobacter, Pseudomonas aeruginosa, enterobacter agglomerans, serratia marcesens, Salmonella typhi, Bacillus proteus, dysentery bacterium is had a liking for the Fructus Hordei Germinatus Flavobacterium, bacteroides fragilis, moraxelle catarrhalis causes.
More preferably by streptococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, hemophilus influenzae, escherichia coli, dysentery bacterium, Pseudomonas aeruginosa, serratia marcesens, Salmonella typhi, moraxelle catarrhalis cause catching of above-mentioned animal or human.
Claims (7)
1. the purposes of the fluoroquinolone compound of a phosphoric acid ester group aspect preparation treatment infectious disease medicament, the fluoroquinolone compound of described phosphoric acid ester group has the described structure of following general formula I:
Wherein: R
1For H, can slough or the blocking group of hydrolysis or the benzyl shown in the general formula (II), and can substituted benzyl;
R
2Be H, NO
2, NH
2, halogen atom, C
1-C
3Alkyl, C
1-C
3Alkoxyl group or C
1-C
3Alkylamino radical;
5 methyl in the above-mentioned general formula I can be (S)-configuration or (R)-configuration or (R/S)-configurations.
2. purposes according to claim 1 is characterized in that, the carbostyril compound of described general formula I is (S)-(-)-9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 7)
Perhaps be 9-fluoro-8-[4-(phosphate-based)-1-piperidines]-5-methyl isophthalic acid-oxygen-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid (compound 10).
3. purposes according to claim 1 and 2, it is characterized in that, the carbostyril compound of described general formula I comprises raceme, various optical isomer, all cpds crystal formation, pharmacy acceptable salt, pharmaceutically acceptable hydrate or solvate, hydrolyzable ester, contains the pharmaceutical composition of compound shown in the general formula (I).
4. purposes according to claim 1 and 2 is characterized in that, described pharmacy acceptable salt can be sodium salt, sylvite, calcium salt, ammonium salt, methylamine salt, ethylamine salt, ethanolamine salt, lysine salt, arginic acid salt or ornithine salt.
5. according to each described purposes of claim 1-4, it is characterized in that described infectious diseases is the animal or human's that caused by aerobic gram-positive microorganism, aerobic gram-negative bacteria, anaerobism gram-positive microorganism or anaerobism Gram-negative bacteria a infectious diseases.
6. purposes according to claim 5 is characterized in that described infectious diseases is by streptococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, the osculant staphylococcus, Staphylococcus saprophyticus, A group streptococcus (micrococcus scarlatinae), the B group streptococcus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, streptococcus agalactiae, Streptococcus viridans, hemophilus influenzae, haemophilus parainfluenzae, escherichia coli, Klebsiella Pneumoniae, citrobacter, enteroaerogen, enterobacter cloacae, acinetobacter, Pseudomonas aeruginosa, enterobacter agglomerans, serratia marcesens, Salmonella typhi, Bacillus proteus, dysentery bacterium is had a liking for the Fructus Hordei Germinatus Flavobacterium, the animal or human's that bacteroides fragilis, moraxelle catarrhalis cause infectious diseases.
7. purposes according to claim 6 is characterized in that described infectious diseases is by streptococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, enterococcus faecalis, faecium, streptococcus pneumoniae, gonococcus, hemophilus influenzae, escherichia coli, dysentery bacterium, Pseudomonas aeruginosa, serratia marcesens, the animal or human's that Salmonella typhi, moraxelle catarrhalis cause infectious diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100036639A CN101220056A (en) | 2006-07-03 | 2007-01-12 | Use of fluoroquinolone containing phosphoric acid ester group |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610090374.2 | 2006-07-03 | ||
| CN200610090374 | 2006-07-03 | ||
| CNA2007100036639A CN101220056A (en) | 2006-07-03 | 2007-01-12 | Use of fluoroquinolone containing phosphoric acid ester group |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710000558XA Division CN101100474B (en) | 2006-07-03 | 2007-01-12 | Fluoroquinolone compound containing phosphate ester group and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101220056A true CN101220056A (en) | 2008-07-16 |
Family
ID=39630161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100036624A Expired - Fee Related CN101220055B (en) | 2006-07-03 | 2007-01-12 | Method for preparing fluoroquinolone compounds containing phosphoric acid ester group |
| CNA2007100036639A Pending CN101220056A (en) | 2006-07-03 | 2007-01-12 | Use of fluoroquinolone containing phosphoric acid ester group |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100036624A Expired - Fee Related CN101220055B (en) | 2006-07-03 | 2007-01-12 | Method for preparing fluoroquinolone compounds containing phosphoric acid ester group |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101220055B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923125A (en) * | 2014-03-31 | 2014-07-16 | 哈尔滨工业大学 | Water-soluble porphyrin photosensitizer and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787322B1 (en) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | OIL-IN-WATER EMULSION COMPRISING A MICRONIZED ACTIVE AGENT AND AN APPROPRIATE EMULSION SYSTEM |
| US6750224B1 (en) * | 1999-05-07 | 2004-06-15 | Wockhardt Limited | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment |
-
2007
- 2007-01-12 CN CN2007100036624A patent/CN101220055B/en not_active Expired - Fee Related
- 2007-01-12 CN CNA2007100036639A patent/CN101220056A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101220055B (en) | 2011-09-07 |
| CN101220055A (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1322648B1 (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | |
| US4886810A (en) | Quinoline derivatives, pharmaceutical composition and method of use | |
| SU1598873A3 (en) | Method of producing derivatives of quinoline or their pharmaceutically acceptable esters or acid-additive salts | |
| AU2002212614A1 (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | |
| EP0132845A2 (en) | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | |
| CN101100474B (en) | Fluoroquinolone compound containing phosphate ester group and its preparation method and use | |
| CN105884752B (en) | And ring class gyrase and topoisomerase I V inhibitor | |
| EP0191451B1 (en) | Novel 1,8-naphthyridine derivatives and processes for preparation thereof | |
| SK132193A3 (en) | Antibiotic compounds | |
| CN101220055B (en) | Method for preparing fluoroquinolone compounds containing phosphoric acid ester group | |
| EP0312085B1 (en) | Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them | |
| CN104098588B (en) | One class three is encircled Carbostyril derivative and its production and use | |
| EP0266896B1 (en) | 7-( (meta-substituted) phenylglycine) 1-carba-1-dethiacephalosporins | |
| US20030069417A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| EP0812838B1 (en) | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor | |
| US20030088094A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| KR100274736B1 (en) | Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin | |
| EP3634974B1 (en) | Tunicamycin analogues | |
| KR0166179B1 (en) | Novel quinolone carboxylic acid derivative and process for the preparation thereof | |
| CN101450947B (en) | 7-(3-oximido-4-amido-4-alkyl-1-piperidine)quinoline carboxylic acid derivates and preparation method thereof | |
| US20040176591A1 (en) | Novel synthesis and crystallization of peperazine ring-containing compounds | |
| WO2014133412A2 (en) | (3r,4r,5s)-4-amino-5-(2,2-difluoroacetylamino)-3-(1-ethylpropoxy)-cyclohex-1-enecarboxylic acid and esters thereof, and method for producing and using same | |
| KR19980076903A (en) | New Quinolone Carboxylic Acid Derivatives | |
| CA2005015A1 (en) | Quinolonecarboxylic acid derivative, preparation thereof and pharmaceutical composition containing the derivative | |
| KR19990011423A (en) | Novel cefem derivatives, their preparation and their use as antimicrobial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080716 |